



OPEN ACCESS

EDITED AND REVIEWED BY

S. Paul Gao,
Memorial Sloan Kettering Cancer Center,
United States

*CORRESPONDENCE

Gianluca Fossati
✉ g.fossati@italfarmacogroup.com

[†]These authors have contributed
equally to this work and share
first authorship

RECEIVED 12 June 2025

ACCEPTED 21 July 2025

PUBLISHED 05 August 2025

CITATION

Spadotto V, Ripamonti C, Ghiroldi A,
Galbiati E, Pozzi P, Noberini R, Bonaldi T,
Steinkühler C and Fossati G (2025)
Correction: HDAC6 inhibition by ITF3756
modulates PD-L1 expression and monocyte
phenotype: insights for a promising immune
checkpoint blockade co-treatment therapy.
Front. Immunol. 16:1645773.
doi: 10.3389/fimmu.2025.1645773

COPYRIGHT

© 2025 Spadotto, Ripamonti, Ghiroldi, Galbiati,
Pozzi, Noberini, Bonaldi, Steinkühler and
Fossati. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](#). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Correction: HDAC6 inhibition by ITF3756 modulates PD-L1 expression and monocyte phenotype: insights for a promising immune checkpoint blockade co-treatment therapy

Valeria Spadotto^{1†}, Chiara Ripamonti^{1†}, Andrea Ghiroldi¹,
Elisabetta Galbiati², Pietro Pozzi², Roberta Noberini³,
Tiziana Bonaldi^{3,4}, Christian Steinkühler¹ and Gianluca Fossati^{1*}

¹New Drug Incubator Department, Italfarmaco Group, Milan, Italy, ²Preclinical Drug Development Department, Italfarmaco Group, Milan, Italy, ³Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy, ⁴Department of Oncology and Hematology-Oncology (DIPO), University of Milan, Milan, Italy

KEYWORDS

HDAC6, monocytes, immuno-checkpoints, TNF- α , dendritic cells

A Correction on

HDAC6 inhibition by ITF3756 modulates PD-L1 expression and monocyte phenotype: insights for a promising immune checkpoint blockade co-treatment therapy

By Spadotto V, Ripamonti C, Ghiroldi A, Galbiati E, Pozzi P, Noberini R, Bonaldi T, Steinkühler C and Fossati G (2025). *Front. Immunol.* 16:1546939. doi: 10.3389/fimmu.2025.1546939

In the published article, there was an error in **Figure 6** as published. There was a mistake in the axes of **Figure 6C** and **Figure 6D** as published, and as a result, the list of the genes were not correct. The corrected **Figure 6** and its caption “ITF3756 downregulates monocytes activation and differentiation markers activated by TNF- α and promotes a less immunosuppressive phenotype in TNF- α stimulated monocytes. Purified human monocytes were treated for 2h with ITF3756 (1 μ M) and then stimulated with TNF- α (100ng/ml) for 4h. RNAseq data obtained as described before were used for this analysis. (A) Analysis of the modulation of specific markers of monocytes-derived cell population by TNF- α (left panel) and by the combination of TNF- α and ITF3756 (right panel). Fold changes (FC) are calculated versus the unstimulated control cells or versus the TNF- α stimulated cells, respectively. (B–D) Analysis of the modulation by TNF- α and by the combination of TNF- α and ITF3756 of a list of inhibitory immune checkpoints (31). Fold changes (FC) are calculated versus the unstimulated control cells in (B), versus the TNF- α stimulated cells in (C) and between ITF3756 and unstimulated control cells in (D). Significant differentially expressed genes are represented as circles, while non-significant genes are shown as triangles” appear below.

The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 6
ITF3756 downregulates monocytes activation and differentiation markers activated by TNF- α and promotes a less immunosuppressive phenotype in TNF- α stimulated monocytes. Purified human monocytes were treated for 2h with ITF3756 (1 μ M) and then stimulated with TNF- α (100ng/ml) for 4h. RNAseq data obtained as described before were used for this analysis. **(A)** Analysis of the modulation of specific markers of monocytes-derived cell population by TNF- α (left panel) and by the combination of TNF- α and ITF3756 (right panel). Fold changes (FC) are calculated versus the unstimulated control cells or versus the TNF- α stimulated cells, respectively. **(B–D)** Analysis of the modulation by TNF- α and by the combination of TNF- α and ITF3756 of a list of inhibitory immune checkpoints (31). Fold changes (FC) are calculated versus the unstimulated control cells in **(B)**, versus the TNF- α stimulated cells in **(C)** and between ITF3756 and unstimulated control cells in **(D)**. Significant differentially expressed genes are represented as circles, while non-significant genes are shown as triangles.